The largest database of trusted experimental protocols

8 protocols using t2577

1

Temozolomide Dosage Preparation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Temozolomide (TMZ) experiments were adapted from previously established protocols (Knobloch et al., 2014 (link), Garthe et al., 2009 (link)). Stock solutions of TMZ (Sigma T2577) were dissolved fresh in DMSO at 25 mg/mL, and further diluted to 5 mg/mL in PBS the day of injections.
+ Open protocol
+ Expand
2

Glioblastoma Multimodal Therapy: In Vivo RCT

Check if the same lab product or an alternative is used in the 5 most similar protocols
In vivo RCT started seven days after glioblastoma cell implantation when the tumor volume was around 2–5 mm3. Mice were treated thrice with chemotherapy (TMZ, T2577, Sigma Aldrich, St Quentin Fallavier, France) and radiotherapy (X-rays). Each fraction of RCT was spaced at 48 h. TMZ (10 mg/kg/day in saline) was administered intraperitoneally. Control animals received the same volume of saline solution (vehicle). Two hours later, ipsilateral hemisphere of mice was irradiated with the X-RAD225 Cx system (Precision X-ray Inc, CYCERON platform, Caen, France) at 4 Gy/day with a dose rate of 3.3 Gy/min. The characteristics of the photon beam delivered by this small animal irradiator were voltage = 225 keV, intensity = 13.3 mA, and energy = 80 keV using 1 mm Cu filter. The schedule of protocol is illustrated in Figure 1A.
+ Open protocol
+ Expand
3

Sarcoma Organoid Drug Screening

Check if the same lab product or an alternative is used in the 5 most similar protocols
Therapy screening was initiated on day 7 following organoid biofabrication. Treatments were tailored for each sarcoma subtype based on preoperative biopsies or final surgical pathology. The number of therapies and doses involved varied based on available cells. The therapies used for sarcoma organoids were doxorubicin (0.1, 1, 10 μM) [S1208, Selleckchem, Houston, TX, USA], ifosfamide (2, 20, 200 μM) [I4909, Sigma-Aldrich], temozolomide (10, 100, 1000 μM) [T2577, Sigma-Aldrich], imatinib mesylate (1, 10, 100 μM) [STI571, Selleckchem], regorafenib (0.1, 1, 10 μM) [S1178, Selleckchem], gemcitabine (1, 10, 100 μM) [G6423, Sigma-Aldrich], olaparib (0.1, 1, 10 μM) [S1060, Selleckchem], 100 nM pembrolizumab (A2005, Selleckchem,), 100 nM nivolumab (A2002, Selleckchem), and 100 nM ipilimumab (A2001, Selleckchem). Drug containing-media was added to organoid wells for 72 h, followed by viability assays.
+ Open protocol
+ Expand
4

Quantifying TP73-AS1 Knockdown Effects

Check if the same lab product or an alternative is used in the 5 most similar protocols
The kd of TP73-AS1 was induced by addition of doxycycline for 10 days. The cells were plated in 12-well plates and TMZ (Sigma-Aldrich, T2577) or DMSO was added. Seven to ten days post treatment, the cells were washed and trichloroacetic acid (TCA) was added for an hour at 4 °C. The plates were washed and air dried. Crystal Violet (C0075, Sigma-Aldrich) was added for half an hour and additional rinsing was conducted. After dehydration, 10% acetic acid was added and the optical density was measured at 570 nm. The results were normalized to scramble gRNA.
+ Open protocol
+ Expand
5

Multicellular Spheroid Generation and TMZ Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols
SK‐MEL‐28 multicellular spheroids were generated using the “hanging drop” method.
38 (link),
39 (link) Briefly, cells were cultured and added in suspension at 2–2.5 × 104 cells/mL. Next, around 500 cells were placed on the inside cover of a 100‐mm culture dish as hanging drops (20 μL) and left for 48 h. The formed spheroids were transferred into a 96‐well plate,
38 (link),
39 (link) and culture medium was then added (in the absence (DMSO used as vehicle; control) or presence of TMZ (Sigma, #T2577) at 80 μg/mL (TMZ‐C1) or 200 μg/mL [TMZ‐C2]). Images were taken after 24 h and every other day, using a Leica inverted DMi1 microscope. The spheroid surface area was measured (12 spheroid measurements/condition) using the ICY Bioimage analysis software (https://icy.bioimageanalysis.org/). Ten spheroids (day 6) were selected per each condition for further ELISA measurements.
+ Open protocol
+ Expand
6

Preparation of Anticancer Drug Solutions

Check if the same lab product or an alternative is used in the 5 most similar protocols
The drugs used in the study were dissolved in their respective solvents as reported in the product information. Specifically, temozolomide (Sigma-Aldrich, T2577) and enzastaurin (Sigma-Aldrich, SML0762) were dissolved in DMSO (Sigma-Aldrich, D8418), while imatinib (Sigma-Aldrich, SML1027) was dissolved in sterile milliQ water.
+ Open protocol
+ Expand
7

Cytotoxicity of Anti-Cancer Drugs

Check if the same lab product or an alternative is used in the 5 most similar protocols
G55 GBM cells were treated with Doxorubicin (17μM) overnight or Temozolomide (TMZ, 0.25 mM, 0.5 mM, and 1 mM, T2577, Sigma) for 72 hours at 37°C. MDA-MB-231 cells were incubated with Doxorubicin (17μM) overnight or 5-Fluorouracil (5-Fu, 25μM, Sigma-Aldrich) for 72 hours. Cell viability under various anti-cancer drug treatments was determined with the Green Live/Dead Stain (34J66, ImmunoChemistry) with 1:1,000 (v/v) in 1xPBS.
+ Open protocol
+ Expand
8

Cytotoxicity Assay of GBM Treatments

Check if the same lab product or an alternative is used in the 5 most similar protocols
U87 and U343 cells were plated as monolayers in 96-well plates (4000 cells/well) and treated with indicated concentrations of CYC065 (#HY-101212, Medchemexpress, NJ, US) and THZ1 (#HY-80013, Medchemexpress, NJ, US) for 72 h. Patient-derived GBM cultures were plated in 96-well plates as gliomaspheres (3000 cells/well) and treated with indicated concentrations of CYC065, THZ1 and/or TMZ (#T2577, Sigma-Aldrich, Arklow, Ireland) and S-63845 (#S8383, Selleck Chemicals, Houston, TX, US) as indicated for 72 h. Mouse primary cortical neurons were seeded in flat-bottom 96-well plates coated with poly-L-lysine as 30,000 cells/well and treated with increasing concentrations of CYC065 and THZ1 for 96 h. Following treatment, WST-1 reagent (Sigma-Aldrich, Arklow, Ireland) was added in 1:10 final dilution, according to the manufacturer’s instructions. WST-1 salt is cleaved to a soluble formazan dye by a NAD(P)H-dependent reaction in viable cells. Plates were incubated for 2 h in a humidified incubator at 37 °C and 5% CO2 and the absorbance of each sample was measured at 450 and 620 nm using a microplate reader (GENios, Tecan, Weymouth, UK). Background signal (620 nm) was then subtracted from the 450 nm reads. The absorbance was proportional to the number of viable cells and expressed relative to DMSO (0.1%) control-treated groups.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!